Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668265 · ClinicalTrials.gov registry record · Phase 4
Anxiety in Recovering Opiate Dependence
A Phase 4 study, sponsored by Beth Israel Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00668265 is a Phase 4 study that was terminated before completion, run by Beth Israel Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT00668265, a Phase 4 study, was terminated before completion, sponsored by Beth Israel Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a 16 week study of the efficacy of quetiapine in treating symptoms of generalized anxiety disorder (GAD) in subjects with comorbid opiate dependence. The study will be conducted in a prospective, randomized, double-blind, and placebo-controlled fashion. Study subjects will be inpatients at a residential drug-treatment facility, enrolled in a 1 year methadone-to-abstinence treatment plan. Subjects will be randomized to receive either quetiapine or placebo in addition to ongoing drug addiction treatment. Subjects will be followed for 16 weeks and a variety of psychometric assessments will be made. Hypothesis One: Compared to placebo, Quetiapine will demonstrate a greater reduction in symptoms of anxiety in subjects with GAD and remitted comorbid opiate abuse. Exploratory Hypotheses: Compared to placebo, Quetiapine will demonstrate a greater improvement in psychosocial functioning and compliance with community norms in subjects enrolled in a residential drug addiction treatment facility.
Interventions
- DRUG Quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00668265
The ClinicalTrials.gov registry entry for NCT00668265 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Medical Center, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quetiapine is the first listed.
NCT00668265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00668265 about?
NCT00668265 is a clinical study titled "Anxiety in Recovering Opiate Dependence". This is a 16 week study of the efficacy of quetiapine in treating symptoms of generalized anxiety disorder (GAD) in subjects with comorbid opiate dependence. The study will be conducted in a prospective, randomized, double-blind, and placebo-controlled fashion. Study subjects will be inpatients at a...
What is the current status of trial NCT00668265?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2008-01. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00668265?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00668265?
This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.